PARP1 and colorectal carcinoma: Considering the synthetic lethality of PARP-1 inhibitors against BRCA-deficient cells, it can be seen that the inhibition ratio of these two compounds is significantly higher in HCT-116 than RKO in the colorectal carcinoma cell lines, which is also consistent with the results of Niraparib.